89 related articles for article (PubMed ID: 34177962)
21. Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.
Schasfoort RBM; van Weperen J; van Amsterdam M; Parisot J; Hendriks J; Koerselman M; Karperien M; Mentink A; Bennink M; Krabbe H; Terstappen LW; Mulder AHL
Biosens Bioelectron; 2021 Jul; 183():113165. PubMed ID: 33799060
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometry detection of sustained humoral immune response (IgG + IgA) against native spike glycoprotein in asymptomatic/mild SARS-CoV-2 infection.
Piñero P; Marco De La Calle FM; Horndler L; Alarcón B; Uribe Barrientos M; Sarmiento H; Tarín F
Sci Rep; 2021 May; 11(1):10716. PubMed ID: 34021205
[TBL] [Abstract][Full Text] [Related]
23. Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection.
Ivanov A; Semenova E
J Med Virol; 2021 Oct; 93(10):5953-5960. PubMed ID: 34185312
[TBL] [Abstract][Full Text] [Related]
24. Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection.
Pullen KM; Atyeo C; Collier AY; Gray KJ; Belfort MB; Lauffenburger DA; Edlow AG; Alter G
Cell Rep; 2021 Nov; 37(6):109959. PubMed ID: 34739850
[TBL] [Abstract][Full Text] [Related]
25. IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients.
Staats LAN; Pfeiffer H; Knopf J; Lindemann A; Fürst J; Kremer AE; Hackstein H; Neurath MF; Muñoz LE; Achenbach S; Leppkes M; Herrmann M; Schett G; Steffen U
Cells; 2020 Dec; 9(12):. PubMed ID: 33322797
[TBL] [Abstract][Full Text] [Related]
26. IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10.
Young MK; Kornmeier C; Carpenter RM; Natale NR; Sasson JM; Solga MD; Mathers AJ; Poulter MD; Qiang X; Petri WA
medRxiv; 2020 Dec; ():. PubMed ID: 33330878
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study.
Parker E; Thomas J; Roper KJ; Ijaz S; Edwards T; Marchesin F; Katsanovskaja K; Lett L; Jones C; Hardwick HE; Davis C; Vink E; McDonald SE; Moore SC; Dicks S; Jegatheesan K; Cook NJ; Hope J; Cherepanov P; McClure MO; Baillie JK; Openshaw PJM; Turtle L; Ho A; Semple MG; Paxton WA; Tedder RS; Pollakis G;
Front Immunol; 2023; 14():1146702. PubMed ID: 37056776
[TBL] [Abstract][Full Text] [Related]
28. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity.
Abela IA; Pasin C; Schwarzmüller M; Epp S; Sickmann ME; Schanz MM; Rusert P; Weber J; Schmutz S; Audigé A; Maliqi L; Hunziker A; Hesselman MC; Niklaus CR; Gottschalk J; Schindler E; Wepf A; Karrer U; Wolfensberger A; Rampini SK; Meyer Sauteur PM; Berger C; Huber M; Böni J; Braun DL; Marconato M; Manz MG; Frey BM; Günthard HF; Kouyos RD; Trkola A
Nat Commun; 2021 Nov; 12(1):6703. PubMed ID: 34795285
[TBL] [Abstract][Full Text] [Related]
29. EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity.
Bereczki D; Nagy B; Kerényi A; Nagy G; Szarka K; Kristóf K; Szalay B; Vásárhelyi B; Bhattoa HP; Kappelmayer J
Lab Med; 2022 Mar; 53(2):206-209. PubMed ID: 34415328
[TBL] [Abstract][Full Text] [Related]
30. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.
Wei J; Matthews PC; Stoesser N; Maddox T; Lorenzi L; Studley R; Bell JI; Newton JN; Farrar J; Diamond I; Rourke E; Howarth A; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Pouwels KB; Walker AS; Eyre DW;
Nat Commun; 2021 Oct; 12(1):6250. PubMed ID: 34716320
[TBL] [Abstract][Full Text] [Related]
31. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2.
Klingler J; Weiss S; Itri V; Liu X; Oguntuyo KY; Stevens C; Ikegame S; Hung CT; Enyindah-Asonye G; Amanat F; Baine I; Arinsburg S; Bandres JC; Kojic EM; Stoever J; Jurczyszak D; Bermudez-Gonzalez M; Nádas A; Liu S; Lee B; Zolla-Pazner S; Hioe CE
medRxiv; 2020 Dec; ():. PubMed ID: 33173891
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG.
Jamiruddin MR; Haq MA; Tomizawa K; Kobatake E; Mie M; Ahmed S; Khandker SS; Ali T; Jahan N; Oishee MJ; Khondoker MU; Sil BK; Haque M; Adnan N
J Inflamm Res; 2021; 14():2497-2506. PubMed ID: 34163208
[TBL] [Abstract][Full Text] [Related]
33. Viral and immunologic evaluation of smokers with severe COVID-19.
Vecchio J; Regan J; Jiang Y; Li R; Romain H; Yousuf F; Adel T; Hall K; DaCosta JM; Yu X; Li JZ; Fofana IB
Sci Rep; 2023 Oct; 13(1):17898. PubMed ID: 37857680
[TBL] [Abstract][Full Text] [Related]
34. Two-trace two-dimensional correlation spectra (2T2D-COS) analysis using FTIR spectra to monitor the immune response by COVID-19.
Karthikeyan S; Vazquez-Zapien GJ; Martinez-Cuazitl A; Delgado-Macuil RJ; Rivera-Alatorre DE; Garibay-Gonzalez F; Delgado-Gonzalez J; Valencia-Trujillo D; Guerrero-Ruiz M; Atriano-Colorado C; Lopez-Reyes A; Lopez-Mezquita DJ; Mata-Miranda MM
J Mol Med (Berl); 2024 Jan; 102(1):53-67. PubMed ID: 37947852
[TBL] [Abstract][Full Text] [Related]
35. Serological assays to measure dimeric IgA antibodies in SARS-CoV-2 infections.
Wei Z; Angrisano F; Eriksson EM; Mazhari R; Van H; Zheng S; Center RJ; Boo I; McMahon J; Lau J; Kiernan-Walker N; Ruybal-Pesántez S; Mueller I; Robinson LJ; Anderson DA; Drummer HE
Immunol Cell Biol; 2023 Oct; 101(9):857-866. PubMed ID: 37593973
[TBL] [Abstract][Full Text] [Related]
36. Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure.
Laudanski K; Mahmoud MA; Ahmed AS; Susztak K; Mathew A; Chen J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612525
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin A as a Key Immunological Molecular Signature of Post-COVID-19 Conditions.
Sousa GF; Carpes RM; Silva CAO; Pereira MEP; Silva ACVF; Coelho VAGS; Costa EP; Mury FB; Gestinari RS; Souza-Menezes J; Leal-da-Silva M; Nepomuceno-Silva JL; Tanuri A; Ferreira-Júnior OC; Monteiro-de-Barros C
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515231
[TBL] [Abstract][Full Text] [Related]
38. Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients.
Ijaz S; Dicks S; Jegatheesan K; Parker E; Katsanovskaja K; Vink E; McClure MO; Shute J; Hope J; Cook N; Cherepanov P; Turtle L; Paxton WA; Pollakis G; Ho A; Openshaw PJM; Baillie JK; Semple MG; Tedder RS;
J Infect; 2022 Aug; 85(2):152-160. PubMed ID: 35667482
[No Abstract] [Full Text] [Related]
39. Serum antibody fingerprinting of SARS-CoV-2 variants in infected and vaccinated subjects by label-free microarray biosensor.
Carzaniga T; Casiraghi L; Nava G; Zanchetta G; Inzani T; Chiari M; Bollati V; Epis S; Bandi C; Lai A; Zehender G; Bellini T; Buscaglia M
Front Immunol; 2024; 15():1323406. PubMed ID: 38476234
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of a Highly Sensitive Multiplex Immunoassay for SARS-CoV-2 Humoral Response Monitorization: A Study of the Antibody Response in COVID-19 Patients with Different Clinical Profiles during the First and Second Waves in Cadiz, Spain.
Olvera-Collantes L; Moares N; Fernandez-Cisnal R; Muñoz-Miranda JP; Gonzalez-Garcia P; Gabucio A; Freyre-Carrillo C; Jordan-Chaves JD; Trujillo-Soto T; Rodriguez-Martinez MP; Martin-Rubio MI; Escuer E; Rodriguez-Iglesias M; Fernandez-Ponce C; Garcia-Cozar F
Microorganisms; 2023 Dec; 11(12):. PubMed ID: 38138141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
